Wang, Jinhai

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury

Han, Y., Liao, Z., Li, Y., Zhao, X., Ma, S., Bao, D., Qiu, M., Deng, J., Wang, J., Qu, P., et al. (2022) · Journal of the American College of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesGastrointestinal Bleeding Diagnosis and Treatment

Cited by 77

A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats.

Zhao, J., Wang, J., Dong, L., Shi, H., Wang, Z., Ding, H., Shi, H., & Lu, X. (2011) · European Journal of Pharmacology

Gastrointestinal motility and disordersInflammatory Bowel Disease

Cited by 35